Amgen Battles IRS Over Billions in "Wholly Unwarranted" Tax Penalties

Amgen Battles IRS Over Billions in "Wholly Unwarranted" Tax Penalties

Source: 
BioSpace
snippet: 

Amgen held its earnings conference call on Wednesday for the first quarter of 2022. The company provided updates on its financial status, clinical trials, revenue and most notably, its ongoing litigation with the Internal Revenue Service.